FDA-cleared profile

V8/XV8/XH8, V7/XV7/XH7, V6/XV6/XH6 Diagnostic Ultrasound System

Samsung Medison Co., Ltd. · Ultrasound · FDA-cleared (510(k))

Authorized purpose: The Samsung V8, XV8, XH8, V7, XV7, XH7, V6, XV6, XH6 diagnostic ultrasound systems provide general diagnostic ultrasound and fluid-flow analysis across fetal, obstetric, abdominal, pediatric, small-organ, cardiac, vascular, musculoskeletal, urologic, thoracic, transrectal, transvaginal, transesophageal, and intraoperative applications.

Clinical role
Ultrasound acquisition, measurement, analysis, reporting, and release-specific AI assistance.
Images and patients
Ultrasound · Multi-region
Key limitation
Keep in mind: It is intended for use by, or by the order of, and under the supervision of, an appropriately trained healthcare professional who is qualified for direct use of medical devices.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: The Samsung V8, XV8, XH8, V7, XV7, XH7, V6, XV6, XH6 diagnostic ultrasound systems provide general diagnostic ultrasound and fluid-flow analysis across fetal, obstetric, abdominal, pediatric, small-organ, cardiac, vascular, musculoskeletal, urologic, thoracic, transrectal, transvaginal, transesophageal, and intraoperative applications.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Multi-region Input: The diagnostic ultrasound system and transducers are designed to obtain ultrasound images and analyze body fluids.
  • Who uses it?Intended users: It is intended for use by, or by the order of, and under the supervision of, an appropriately trained healthcare professional who is qualified for direct use of medical devices.
  • What does the software produce?Output: The V8/XV8/XH8, V7/XV7/XH7, V6/XV6/XH6 diagnostic ultrasound system function is to acquire ultrasound data and to display the data as 2D mode, Color Doppler mode, Power Doppler (PD) mode, M mode, Pulsed Wave (PW) Doppler mode, Continuous Wave (CW) Doppler mode, Tissue Doppler Imaging (TDI) mode, Tissue Doppler Wave (TDW) mode, ElastoScan Mode, Combined modes, Multi-Image mode (Dual, Quad), 3D/4D mode. The system also gives the operator the ability to measure anatomical structures and offer analysis packages that provide information that is used to make a diagnosis by competent health care professionals.
  • What is its most important limitation?Key limitation: It is intended for use by, or by the order of, and under the supervision of, an appropriately trained healthcare professional who is qualified for direct use of medical devices.

Clinical takeaway. Clinical role: The Samsung V8, XV8, XH8, V7, XV7, XH7, V6, XV6, XH6 diagnostic ultrasound systems provide general diagnostic ultrasound and fluid-flow analysis across fetal, obstetric, abdominal, pediatric, small-organ, cardiac, vascular, musculoskeletal, urologic, thoracic, transrectal, transvaginal, transesophageal, and intraoperative applications.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical evaluation of acoustic output, biocompatibility, software function, cleaning and disinfection, and thermal, electrical, electromagnetic and mechanical safety. For the AI-based NerveTrack feature, testing against ground truth from anesthesiologists and sonographers reported nerve detection accuracy (%) 90.3 (95% CI 87.28 to 93.33) and segmentation accuracy (%) 98.42 (95% CI 97.13 to 99.71). Clinical studies were not required. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
The Samsung V8, XV8, XH8, V7, XV7, XH7, V6, XV6, XH6 diagnostic ultrasound systems provide general diagnostic ultrasound and fluid-flow analysis across fetal, obstetric, abdominal, pediatric, small-organ, cardiac, vascular, musculoskeletal, urologic, thoracic, transrectal, transvaginal, transesophageal, and intraoperative applications.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Ultrasound acquisition, measurement, analysis, reporting, and release-specific AI assistance.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
The diagnostic ultrasound system and transducers are designed to obtain ultrasound images and analyze body fluids.
  • Exact FDA submission
  • Checked 2026-09-19

The exact indications establish ultrasound images, body-fluid analysis, and transducers; imported-data and host-device wording is not stated.

Output and clinician action
The V8/XV8/XH8, V7/XV7/XH7, V6/XV6/XH6 diagnostic ultrasound system function is to acquire ultrasound data and to display the data as 2D mode, Color Doppler mode, Power Doppler (PD) mode, M mode, Pulsed Wave (PW) Doppler mode, Continuous Wave (CW) Doppler mode, Tissue Doppler Imaging (TDI) mode, Tissue Doppler Wave (TDW) mode, ElastoScan Mode, Combined modes, Multi-Image mode (Dual, Quad), 3D/4D mode. The system also gives the operator the ability to measure anatomical structures and offer analysis packages that provide information that is used to make a diagnosis by competent health care professionals.
  • Exact FDA submission
  • Checked 2026-09-19

The exact device description supports acquisition, display modes, measurements, and analysis packages, but not the current clips, overlay, and configured-automated-result wording.

Care setting
Hospitals, clinics, offices, operating rooms, and point-of-care environments within the cleared applications.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
It is intended for use by, or by the order of, and under the supervision of, an appropriately trained healthcare professional who is qualified for direct use of medical devices.
  • Exact FDA submission
  • Checked 2026-09-19

The exact indications identify an appropriately trained healthcare professional and supervision boundary, not the dossier's named physician and sonographer classes.

Limitations
It is intended for use by, or by the order of, and under the supervision of, an appropriately trained healthcare professional who is qualified for direct use of medical devices.
  • Exact FDA submission
  • Checked 2026-09-19

The packet states the direct-use qualification and supervision boundary; it does not state the current AI interpretation limitation.

Evidence summary
The exact FDA document reports non-clinical evaluation of acoustic output, biocompatibility, software function, cleaning and disinfection, and thermal, electrical, electromagnetic and mechanical safety. For the AI-based NerveTrack feature, testing against ground truth from anesthesiologists and sonographers reported nerve detection accuracy (%) 90.3 (95% CI 87.28 to 93.33) and segmentation accuracy (%) 98.42 (95% CI 97.13 to 99.71). Clinical studies were not required. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The device has been evaluated for acoustic output, biocompatibility, software function, cleaning and disinfection effectiveness as well as thermal, electrical, electromagnetic and mechanical safety," … "Acceptance Criteria: Validation Type Definition Acceptance Criteria Number of correctly detected frames Accuracy (%) × 100 ≥ 80%". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports non-clinical evaluation of acoustic output, biocompatibility, software function, cleaning and disinfection, and thermal, electrical, electromagnetic and mechanical safety. For the AI-based NerveTrack feature, testing against ground truth from anesthesiologists and sonographers reported nerve detection accuracy (%) 90.3 (95% CI 87.28 to 93.33) and segmentation accuracy (%) 98.42 (95% CI 97.13 to 99.71). Clinical studies were not required. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The device has been evaluated for acoustic output, biocompatibility, software function, cleaning and disinfection effectiveness as well as thermal, electrical, electromagnetic and mechanical safety," … "Acceptance Criteria: Validation Type Definition Acceptance Criteria Number of correctly detected frames Accuracy (%) × 100 ≥ 80%". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K240631 FDA performance package for V8/XV8/XH8, V7/XV7/XH7, V6/XV6/XH6 Diagnostic Ultrasound System

  • DesignManufacturer ultrasound-system, software, image-quality, and functional verification and validation
  • PopulationBroad adult and pediatric diagnostic ultrasound and fluid-flow applications on the listed Samsung systems
  • Scopeexact submission
  • Tested versionSamsung V8/XV8/XH8, V7/XV7/XH7, and V6/XV6/XH6 Diagnostic Ultrasound Systems
  • IndependenceSponsor or vendor study

K240631

Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

3 unlinked candidate evidence records are retained for source review and excluded from this evidence display.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K240631 by exact submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: The diagnostic ultrasound system and transducers are designed to obtain ultrasound images and analyze body fluids.

    Scope: Exact FDA submission. The exact indications establish ultrasound images, body-fluid analysis, and transducers; imported-data and host-device wording is not stated.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K240631: V8/XV8/XH8, V7/XV7/XH7, V6/XV6/XH6 Diagnostic Ultrasound System

  2. Routing

    Source context, not route validation: Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.

    Scope: Product family. Current vendor materials are product-family evidence for K240631; confirm the exact cleared version, enabled options, deployment, and local compatibility.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K240631: V8/XV8/XH8, V7/XV7/XH7, V6/XV6/XH6 Diagnostic Ultrasound System · Samsung V8 diagnostic ultrasound system overview

  3. AI processing

    Source context, not route validation: Ultrasound hardware or software with supported probes, host devices, licensed options, and network configuration.

    Scope: Product family. Current vendor materials are product-family evidence for K240631; confirm the exact cleared version, enabled options, deployment, and local compatibility.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K240631: V8/XV8/XH8, V7/XV7/XH7, V6/XV6/XH6 Diagnostic Ultrasound System · Samsung V8 diagnostic ultrasound system overview

  4. Returned objects

    Source context, not route validation: The V8/XV8/XH8, V7/XV7/XH7, V6/XV6/XH6 diagnostic ultrasound system function is to acquire ultrasound data and to display the data as 2D mode, Color Doppler mode, Power Doppler (PD) mode, M mode, Pulsed Wave (PW) Doppler mode, Continuous Wave (CW) Doppler mode, Tissue Doppler Imaging (TDI) mode, Tissue Doppler Wave (TDW) mode, ElastoScan Mode, Combined modes, Multi-Image mode (Dual, Quad), 3D/4D mode. The system also gives the operator the ability to measure anatomical structures and offer analysis packages that provide information that is used to make a diagnosis by competent health care professionals.

    Scope: Exact FDA submission. The exact device description supports acquisition, display modes, measurements, and analysis packages, but not the current clips, overlay, and configured-automated-result wording.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K240631: V8/XV8/XH8, V7/XV7/XH7, V6/XV6/XH6 Diagnostic Ultrasound System

  5. Viewer/worklist/report

    Unresolved route: The V8/XV8/XH8, V7/XV7/XH7, V6/XV6/XH6 diagnostic ultrasound system function is to acquire ultrasound data and to display the data as 2D mode, Color Doppler mode, Power Doppler (PD) mode, M mode, Pulsed Wave (PW) Doppler mode, Continuous Wave (CW) Doppler mode, Tissue Doppler Imaging (TDI) mode, Tissue Doppler Wave (TDW) mode, ElastoScan Mode, Combined modes, Multi-Image mode (Dual, Quad), 3D/4D mode. The system also gives the operator the ability to measure anatomical structures and offer analysis packages that provide information that is used to make a diagnosis by competent health care professionals.

    Scope: Exact FDA submission. The exact device description supports acquisition, display modes, measurements, and analysis packages, but not the current clips, overlay, and configured-automated-result wording.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K240631: V8/XV8/XH8, V7/XV7/XH7, V6/XV6/XH6 Diagnostic Ultrasound System

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Ultrasound hardware or software with supported probes, host devices, licensed options, and network configuration.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K240631; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Integration
Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K240631; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Security
Samsung Healthcare USA's security advisories page, published under Boston Imaging (a Samsung company), posts vulnerability impact analyses and patch process statements for Samsung computed tomography, ultrasound and digital radiography modalities (including Log4j, Urgent11, BlueKeep and WannaCry analyses).
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: owning-domain press releases on usa.samsunghealthcare.com state that Boston Imaging is Samsung Medison's U.S. medical imaging business (unified as Samsung HME America, March 2026) and that Samsung Medison is an affiliate of Samsung Electronics. Corporate program statement; exact-release scope is not established.

Training
Only qualified physicians, sonographers, and other trained ultrasound professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: AI-assisted measurements, views, and guidance do not replace image-quality assessment or clinician interpretation; supported probes, host devices, populations, and features differ by release.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K240631; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled AI functions to K240631 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.

product family · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. AI-assisted measurements, views, and guidance do not replace image-quality assessment or clinician interpretation; supported probes, host devices, populations, and features differ by release.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: AI-assisted measurements, views, and guidance do not replace image-quality assessment or clinician interpretation; supported probes, host devices, populations, and features differ by release.

product family · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K240631
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-06-21
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
14Source classes checked
7Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 7 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 7 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

15 sources - 3 history items

Source ledger

  1. FDA K240631: V8/XV8/XH8, V7/XV7/XH7, V6/XV6/XH6 Diagnostic Ultrasound System

    U.S. Food and Drug Administration - Published 2024-06-21 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, intendedUsers, input, output, limitations, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Samsung V8 diagnostic ultrasound system overview

    Samsung Healthcare - Accessed 2026-09-03

    Scope: productFamily, workflowRole, implementationCapabilities, currentCommercialContext

  8. Optimization of the purine operon and energy generation in Bacillus amyloliquefaciens for guanosine production.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  9. Comparative Proteomic Analysis Reveals the Ascorbate Peroxidase-Mediated Plant Resistance to Verticillium dahliae in Gossypium barbadense.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  10. Multicopper oxidases GbAO and GbSKS are involved in the Verticillium dahliae resistance in Gossypium barbadense.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  11. Quantum spin Hall effect in two-dimensional hydrogenated SnPb alloy films.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  12. Complete genome sequence of Bacillus amyloliquefaciens XH7, which exhibits production of purine nucleosides.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  13. The global transcriptional landscape of Bacillus amyloliquefaciens XH7 and high-throughput screening of strong promoters based on RNA-seq data.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  14. High-Temperature Superconductivity of Thermodynamically Stable Fluorite-Type Hydrides at Ambient Pressure.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  15. Samsung Healthcare USA: Security Advisory

    Boston Imaging (Samsung) - Accessed 2026-10-26

    Scope: security

Research history

  1. K240631 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251963

LOGIQ E10s

Ge Medical Systems Ultrasound and Primary Care Diagnostics

Authorized purpose: LOGIQ E10s is a general-purpose diagnostic ultrasound system supporting the labeled adult, pediatric, cardiac, vascular, abdominal, obstetric, small-organ, musculoskeletal, urologic, and procedural applications.

Modality
Ultrasound
Anatomy
Multi-region
Decision
2025-10-29
FDA-cleared K251985

LOGIQ E10

Ge Medical Systems Ultrasound and Primary Care Diagnostics

Authorized purpose: LOGIQ E10 is a general diagnostic ultrasound system for qualified users across fetal and obstetric, abdominal, gynecologic, pediatric, small-organ, breast, cardiac, vascular, musculoskeletal, urologic, transrectal, transvaginal, transesophageal, and intraoperative applications.

Modality
Ultrasound
Anatomy
Multi-region
Decision
2025-10-29
FDA-cleared K250999

V8 Diagnostic Ultrasound System; cV8 Diagnostic Ultrasound System; V7 Diagnostic Ultrasound System; cV7 Diagnostic Ultrasound System; V6 Diagnostic Ultrasound System; cV6 Diagnostic Ultrasound System; V5 Diagnostic Ultrasound System; cV5 Diagnostic Ultrasound System; V4 Diagnostic Ultrasound System; cV4 Diagnostic Ultrasound System

Samsung Medison Co., Ltd.

Authorized purpose: The Samsung V-family diagnostic ultrasound systems support fetal and obstetric, abdominal, gynecologic, pediatric, small-organ, cephalic, cardiac, thoracic, vascular, musculoskeletal, urologic, transrectal, transvaginal, transesophageal, intraoperative, and dermatologic applications where labeled.

Modality
Ultrasound
Anatomy
Multi-region
Decision
2025-07-18

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history